Per Odin

17.0k total citations · 1 hit paper
243 papers, 9.0k citations indexed

About

Per Odin is a scholar working on Neurology, Epidemiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Per Odin has authored 243 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Neurology, 53 papers in Epidemiology and 34 papers in Cellular and Molecular Neuroscience. Recurrent topics in Per Odin's work include Parkinson's Disease Mechanisms and Treatments (199 papers), Neurological disorders and treatments (137 papers) and Restless Legs Syndrome Research (52 papers). Per Odin is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (199 papers), Neurological disorders and treatments (137 papers) and Restless Legs Syndrome Research (52 papers). Per Odin collaborates with scholars based in Sweden, Germany and United Kingdom. Per Odin's co-authors include К. Ray Chaudhuri, Angelo Antonini, Pablo Martínez‐Martín, Olle Lindvall, Peter Hagell, Björn Öbrink, Patrik Brundin, David J. Brooks, Håkan Widner and Hubert H. Fernandez and has published in prestigious journals such as PLoS ONE, Development and Neurology.

In The Last Decade

Per Odin

236 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

2013 487 citations Per Odin, Angelo Antonini et al. profile →

Peers

Countries citing papers authored by Per Odin

Since Specialization

Citations

This map shows the geographic impact of Per Odin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Odin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Odin more than expected).

Fields of papers citing papers by Per Odin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Odin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Odin. The network helps show where Per Odin may publish in the future.

Co-authorship network of co-authors of Per Odin

This figure shows the co-authorship network connecting the top 25 collaborators of Per Odin. A scholar is included among the top collaborators of Per Odin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Odin. Per Odin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson’s Disease: A Swedish Study on Real-World Use and Costs 2025 ·Neurology and Therapy ·Per Odin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Conversion between NMSS and MDS‐NMS in Parkinson's Disease 2025 ·Movement Disorders ·(unknown), (unknown), К. Ray Chaudhuri, Alexandra Rizos, Carmen Rodríguez‐Blázquez, Eugenia Mamikonyan, Roberta Biundo, Anette Schrag, Daniel Weintraub, Angelo Antonini, Per Odin, Pablo Martínez‐Martín	1
3	Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease 2024 ·European Journal of Neurology ·(unknown), Filip Bergquist, Per Odin, (unknown), Anders Johansson, Ioanna Markaki, Per Svenningsson, Nil Dizdar, Dag Nyholm	3
4	Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study 2024 ·Drugs - Real World Outcomes ·К. Ray Chaudhuri, Jean‐Philippe Azulay, Per Odin, (unknown), Josefa Domingos, Ali Alobaidi, (unknown), (unknown), Juan Carlos Parra, (unknown), (unknown), (unknown), Pablo Martínez‐Martín	31
5	Intercultural Translation and Application of the German Version of King’s Parkinson’s Disease Pain Questionnaire in Fluctuating Parkinson’s Disease 2024 ·Acta Neurologica Scandinavica ·Matthias Löhle, Wolfgang H. Jost, (unknown), Florin Gandor, Alexandra Rizos, Pablo Martínez‐Martín, К. Ray Chaudhuri, Per Odin, Georg Ebersbach, Alexander Storch	3
6	Drug-Induced Cognitive Impairment 2024 ·Drug Safety ·Arne Reimers, Per Odin, (unknown)	8
7	Time to workforce exit after a Parkinson’s disease diagnosis 2023 ·npj Parkinson s Disease ·(unknown), Örjan Dahlström, Maria H Nilsson, Susanne Iwarsson, Per Odin	2
8	Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations 2023 ·Journal of Neural Transmission ·Onanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Ruiz, Per Odin, Peter Riederer, Thomas Müller	9
9	Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration 2023 ·Neuropharmacology ·(unknown), (unknown), Per Odin, (unknown), (unknown), Andreas Jakobsson, M. Angela Cenci	4
10	Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease 2023 ·European Journal of Neurology ·(unknown), Ole‐Martin Fuskevåg, Mathias Toft, (unknown), (unknown), (unknown), (unknown), (unknown), Kristina Rosqvist, Elisabet Størset, Per Odin, Espen Dietrichs, Erik Sveberg Dietrichs, (unknown), (unknown)	10
11	Meaning in Life in Late-Stage Parkinson’s Disease: Results from the Care of Late-Stage Parkinsonism Study (CLaSP) in Six European Countries 2023 ·Journal of Religion and Health ·(unknown), (unknown), Martin Fegg, Joaquim J. Ferreira, Per Odin, Bastiaan R. Bloem, Wassilios G. Meissner, Richard Dodel, Anette Schrag, Stefan Lorenzl	1
12	Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease 2022 ·Neurology ·Filip Bergquist, M. Ehrnebo, Dag Nyholm, Anders Johansson, Fredrik Lundin, Per Odin, Per Svenningsson, Fredrik Hansson, (unknown), Elias Eriksson, Nil Dizdar	15
13	Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health‐Related Quality of Life 2022 ·Movement Disorders Clinical Practice ·Jenny M. Norlin, (unknown), Ulf Persson, Daniel Oudin Åström, Peter Hagell, Pablo Martínez‐Martín, Per Odin	3
14	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries 2022 ·Neurology and Therapy ·Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J. Soileau, (unknown), Stuart Isaacson, Aristide Merola, (unknown), Josefa Domingos, Ali Alobaidi, Yash J. Jalundhwala, (unknown), Juan Carlos Parra, Pavnit Kukreja, Koray Onuk, Lars Bergmann, James Pike, К. Ray Chaudhuri	10
15	Satisfaction with Care in Late Stage Parkinson’s Disease 2019 ·Parkinson s Disease ·Kristina Rosqvist, Peter Hagell, Susanne Iwarsson, Maria H Nilsson, Per Odin	7
16	Mobility device use in people with Parkinson's disease: A 3-year follow-up study 2018 ·Acta Neurologica Scandinavica ·Manzur Kader, Stina B. Jonasson, Susanne Iwarsson, Per Odin, Maria H Nilsson	14
17	Device-Aided Treatment Strategies in Advanced Parkinson's Disease 2017 ·International review of neurobiology ·(unknown), (unknown), (unknown), Per Odin, Angelo Antonini	40
18	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? 2017 ·eNeurologicalSci ·María José Catalán, Angelo Antonini, Matilde Calopa, Ovidiu Băjenaru, Oriol de Fàbregues, Adolfo Mínguez‐Castellanos, Per Odin, J M García-Moreno, Stephen Wørlich Pedersen, Zvezdan Pirtošek, Jaime Kulisevsky	10
19	Pain in Parkinson's disease: Observational study of 225 patients 2011 ·UCL Discovery (University College London) ·(unknown), Alexandra Rizos, (unknown), Y. Naidu, (unknown), Anthony H.V. Schapira, Pablo Martínez‐Martín, Angelo Antonini, Cristian Falup‐Pecurariu, Per Odin, К. Ray Chaudhuri	2
20	Pravidel kan ge lungförändringar. Aktivitetstecken och viktnedgång ingår i bilden 1994 ·Läkartidningen ·Ellen Vinge, Per Odin, (unknown), Håkan Widner, Olle Lindvall	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact